ValuEngine upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning.
A number of other brokerages also recently issued reports on VYGR. BidaskClub upgraded Voyager Therapeutics from a hold rating to a buy rating in a research report on Saturday, August 25th. Canaccord Genuity restated a buy rating and issued a $31.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, July 17th. Morgan Stanley downgraded Voyager Therapeutics from an overweight rating to an equal rating in a research report on Monday, September 10th. BTIG Research restated a buy rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Finally, HC Wainwright set a $30.00 price target on Voyager Therapeutics and gave the stock a buy rating in a research report on Tuesday, July 17th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $30.63.
NASDAQ VYGR opened at $13.63 on Tuesday. The company has a market cap of $458.64 million, a PE ratio of -5.16 and a beta of 3.15. Voyager Therapeutics has a one year low of $11.54 and a one year high of $31.91.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). The company had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.00 million. Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. On average, sell-side analysts predict that Voyager Therapeutics will post -2.87 earnings per share for the current fiscal year.
In other Voyager Therapeutics news, Director Glenn Pierce bought 5,000 shares of Voyager Therapeutics stock in a transaction on Wednesday, September 12th. The shares were acquired at an average price of $18.44 per share, for a total transaction of $92,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James A. Geraghty bought 3,000 shares of Voyager Therapeutics stock in a transaction on Monday, September 10th. The stock was acquired at an average price of $19.39 per share, for a total transaction of $58,170.00. Following the purchase, the director now owns 76,588 shares of the company’s stock, valued at $1,485,041.32. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 11,000 shares of company stock valued at $205,300. 33.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in VYGR. Northern Trust Corp increased its stake in Voyager Therapeutics by 3.2% in the first quarter. Northern Trust Corp now owns 200,378 shares of the company’s stock worth $3,765,000 after purchasing an additional 6,276 shares during the period. BlackRock Inc. increased its stake in Voyager Therapeutics by 18.8% in the first quarter. BlackRock Inc. now owns 1,438,029 shares of the company’s stock worth $27,020,000 after purchasing an additional 227,266 shares during the period. UBS Group AG purchased a new stake in Voyager Therapeutics in the first quarter worth $684,000. Millennium Management LLC increased its stake in Voyager Therapeutics by 124.0% in the first quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock worth $11,613,000 after purchasing an additional 342,148 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Voyager Therapeutics by 919.8% in the second quarter. Acadian Asset Management LLC now owns 32,747 shares of the company’s stock worth $640,000 after purchasing an additional 29,536 shares during the period. Institutional investors and hedge funds own 85.09% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Recommended Story: How can investors find ex-dividend dates?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.